Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in C:\inetpub\wwwroot\technology_detail.php on line 331
 Technology Detail


The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.

Login to TechFinder » 

A Novel Variant of Proteins to Identify and Target Cancer Stem Cells (CSCs)


Stanford Reference:

08-015


Abstract


Cancer stem cells are thought to represent the key cell of origin for tumors. They are a self renewing population that can also further differentiate to make the bulk of the tumor mass. Cancer therapies are thought to be ineffective because they target the bulk of the tumor, not the cancer stem cells. It would be highly desirable to be able to identify these cancer stem cells using specific markers, and then use these markers to develop cancer stem cell specific therapeutics.

Stanford researchers have identified a novel variant of the EGFR protein on cancer stem cells (CSCs) and have shown the variant is present in a wide variety of human tumors including those from the brain, breast, ovary, colon, lung and prostate. They have developed a method to identify and characterize CSCs using the presence of this novel variant and have developed a biospecific antibody that utilizes recombinant antibodies against both this novel variant of the EGFR protein and CD133, a known cancer stem cell marker. These findings represent a novel approach to potential diagnostics and therapeutics for a wide range of human cancers.




Applications


  • Therapeutic - antibody-based agent to prevent or treat cancer by specifically targeting CSCs
  • Diagnostic - detect or characterize a tumor based on presence of EGFR variant
  • Cell purification and screening - purify CSCs from a complex tumor mass; purified cells could be used for identifying anti-cancer agents

Advantages


  • Specific:
    • enhanced targeting of the specific CSC population
    • avoids targeting normal stem cells that express CD133

Publications



    Related Web Links



    Innovators & Portfolio



    Patent Status



    Date Released

     9/24/2014
     

    Licensing Contact


    Mary Albertson, Senior Licensing Associate
    (650) 725-9411 (Direct)
    Login to Request Information

    [-] Map/Timeline

    79-066 Mouse Anti-Human Hybridomas L243, L17F15
    82-008 A Monoclonal Antibody Specific For Mouse Granulocytes
    82-010 A Monoclonal Antibody Specific for the B-220 Surface Glycoprotein in Mouse (RA3-3A1)

    more technologies »

    Related Keywords


    cancer stem cells   therapeutic: anticancer   diagnostic: antibody   08-015   
     

       

      

    Also of Interest...
    79-066 Mouse Anti-Human Hybridomas L243, L17F15
    82-008 A Monoclonal Antibody Specific For Mouse Granulocytes
    82-010 A Monoclonal Antibody Specific for the B-220 Surface Glycoprotein in Mouse (RA3-3A1)

    Recently Viewed...
    S08-015 A Novel Variant of Proteins to Identify and Target Cancer Stem Cells (CSCs)